Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer (MITO-7)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00660842 |
Recruitment Status :
Active, not recruiting
First Posted : April 17, 2008
Last Update Posted : March 24, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ovarian Cancer | Procedure: carboplatin Drug: paclitaxel Drug: carboplatin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 800 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study |
Actual Study Start Date : | November 2008 |
Estimated Primary Completion Date : | November 2024 |
Estimated Study Completion Date : | November 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: A
weekly chemotherapy
|
Drug: carboplatin
AUC 2 IV every week Drug: paclitaxel 60mg/m2 IV every week |
Active Comparator: B
every 3 weeks chemotherapy
|
Procedure: carboplatin
AUC 6 IV day 1 every 21 days Drug: paclitaxel 175 mg/m2 IV day 1 every 21 days |
- quality of life [ Time Frame: weekly for the first 9 weeks of therapy, then every 3 weeks until the completion of therapy ]
- progression free survival [ Time Frame: every 6 months ]
- overall survival [ Time Frame: 24 months ]
- response rate [ Time Frame: after 9 and 18 weeks of therapy ]
- toxicity [ Time Frame: weekly during therapy ]
- describe the frequency and duration of symptoms in 12 months preceding ovarian cancer diagnosis [ Time Frame: at study entry ]
- describe time intervals of prediagnostic sentinel events (onset of persistent symptoms, first physician visit, diagnosis of ovarian cancer) [ Time Frame: at study entry ]
- describe patients' pathway to diagnosis of ovarian cancer according to modified Andersen's model of 'total patient delay' [ Time Frame: at study entry ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Cytologic or histologic diagnosis of ovarian carcinoma of the ovary, fallopian tube or primary peritoneal carcinoma, stage IC-IV
- Indication for chemotherapy
- Age > 18 years
- Life expectancy of at least 3 months
Exclusion Criteria:
- Previous or concomitant malignant malignancy (excluding adequately treated baso-or squamocellular carcinoma of the skin and carcinoma in situ of the cervix, and synchronous endometrioid carcinoma Stage Ib or less for the uterus, with ovarian tumor Stage II or higher)
- Performance Status (ECOG) > or = 3.
- Previous chemotherapy
- Heart disease (congestive heart failure, myocardial infarction within 6 months from study entry, atrioventricular block of any grade, severe arrhythmias)
- Neutrophils < 2000 x mm3, platelets < 100000 x mm3
- Inadequate renal function (creatinine > or = 1.25 x normal values) or liver function (ALT or AST > or = 1.25 x normal values)
- Present or suspected hemorrhagic syndromes
- Inability to comply with protocol and follow-up
- Inability to access study site for clinical visits
- Refusal of informed consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00660842
Principal Investigator: | Sandro Pignata, M.D., Ph.D. | National Cancer Institute, Naples | |
Principal Investigator: | Francesco Perrone, M.D., Ph.D. | National Cancer Institute, Naples | |
Principal Investigator: | Marilina Piccirillo, M.D., | National Cancer Institute, Naples | |
Principal Investigator: | Ciro Gallo, M.D., Ph.D. | University of Campania "Luigi Vanvitelli" |
Responsible Party: | National Cancer Institute, Naples |
ClinicalTrials.gov Identifier: | NCT00660842 |
Other Study ID Numbers: |
MITO-7 2008-001754-40 ( EudraCT Number ) |
First Posted: | April 17, 2008 Key Record Dates |
Last Update Posted: | March 24, 2023 |
Last Verified: | March 2023 |
quality of life weekly therapy neurotoxicity |
Ovarian Neoplasms Carcinoma, Ovarian Epithelial Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female Urogenital Neoplasms Genital Diseases |
Endocrine System Diseases Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Paclitaxel Albumin-Bound Paclitaxel Carboplatin Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |